The next generation of immunotherapy? Innate Pharma targets NK cells
Innate Pharma gains rights to AZ’s recently approved leukaemia drug
Doubts over future of cancer immunotherapy
Future uncertain for Innate and BMS’ troubled lirilumab
French biotech developing cancer immunotherapy with BMS.
Innate and BMS’ immunotherapy fails in phase 2 trial
But BMS dumps combination with Yervoy.
Some good news for BMS with Opdivo + natural killer cell combination